Ribavirin as a tri-targeted antitumor repositioned drug

  • Authors:
    • Erick De la Cruz-Hernandez
    • Jose Luis Medina-Franco
    • Jaenai Trujillo
    • Alma Chavez-Blanco
    • Guadalupe Dominguez-Gomez
    • Enrique Perez-Cardenas
    • Aurora Gonzalez-Fierro
    • Lucia Taja-Chayeb
    • Alfonso Dueñas-Gonzalez
  • View Affiliations

  • Published online on: February 25, 2015     https://doi.org/10.3892/or.2015.3816
  • Pages: 2384-2392
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The aim of the present study was to demonstrate that ribavirin, a known inhibitor of eIF4E and inosine 5'-phosphate dehydrogenase (IMPDH), also inhibits histone methyltransferase zeste homolog 2 (EZH2). A computational searching revealed that ribavirin has a high structural similarity to 3-deazaneplanocin A (DZNep). The growth inhibitory effects of ribavirin as well as its effects upon epigenetic enzymes were evaluated in various cancer cell lines. siRNA assays were used to downregulate eIF4E, EZH2 and IMPDH to determine the contribution of these targets to the growth inhibitory effects of ribavirin. Ribavirin decreased EZH2 expression, inhibited histone methyltransferase activity and decreased H3K27 trimethylation. Ribavirin induced variable growth inhibition in a number of cell lines and downregulation of the targets, EZH2, eIF4E and IMPDH1 and 2 by siRNA led to comparable growth inhibition while no significant further reduction in viability was observed when siRNA transfected cells were treated with ribavirin. The results showed that ribavirin inhibits these cancer targets and should thus be studied for cancer therapy.
View Figures
View References

Related Articles

Journal Cover

May-2015
Volume 33 Issue 5

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
De la Cruz-Hernandez E, Medina-Franco JL, Trujillo J, Chavez-Blanco A, Dominguez-Gomez G, Perez-Cardenas E, Gonzalez-Fierro A, Taja-Chayeb L and Dueñas-Gonzalez A: Ribavirin as a tri-targeted antitumor repositioned drug. Oncol Rep 33: 2384-2392, 2015
APA
De la Cruz-Hernandez, E., Medina-Franco, J.L., Trujillo, J., Chavez-Blanco, A., Dominguez-Gomez, G., Perez-Cardenas, E. ... Dueñas-Gonzalez, A. (2015). Ribavirin as a tri-targeted antitumor repositioned drug. Oncology Reports, 33, 2384-2392. https://doi.org/10.3892/or.2015.3816
MLA
De la Cruz-Hernandez, E., Medina-Franco, J. L., Trujillo, J., Chavez-Blanco, A., Dominguez-Gomez, G., Perez-Cardenas, E., Gonzalez-Fierro, A., Taja-Chayeb, L., Dueñas-Gonzalez, A."Ribavirin as a tri-targeted antitumor repositioned drug". Oncology Reports 33.5 (2015): 2384-2392.
Chicago
De la Cruz-Hernandez, E., Medina-Franco, J. L., Trujillo, J., Chavez-Blanco, A., Dominguez-Gomez, G., Perez-Cardenas, E., Gonzalez-Fierro, A., Taja-Chayeb, L., Dueñas-Gonzalez, A."Ribavirin as a tri-targeted antitumor repositioned drug". Oncology Reports 33, no. 5 (2015): 2384-2392. https://doi.org/10.3892/or.2015.3816